NASDAQ:VRNA Verona Pharma (VRNA) Stock Price, News & Analysis $35.66 +0.29 (+0.82%) (As of 11/15/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Verona Pharma Stock (NASDAQ:VRNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Verona Pharma alerts:Sign Up Key Stats Today's Range$34.71▼$35.9750-Day Range$27.49▼$39.8752-Week Range$11.39▼$40.13Volume988,179 shsAverage Volume1.09 million shsMarket Capitalization$2.85 billionP/E RatioN/ADividend YieldN/APrice Target$43.83Consensus RatingBuy Company OverviewVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.Read More… Financial Prophecy (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Verona Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks49th Percentile Overall ScoreVRNA MarketRank™: Verona Pharma scored higher than 49% of companies evaluated by MarketBeat, and ranked 660th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingVerona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerona Pharma has only been the subject of 4 research reports in the past 90 days.Read more about Verona Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verona Pharma are expected to grow in the coming year, from ($2.11) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma is -18.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma is -18.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma has a P/B Ratio of 21.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verona Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.41% of the outstanding shares of Verona Pharma have been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Verona Pharma has recently decreased by 5.29%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerona Pharma does not currently pay a dividend.Dividend GrowthVerona Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.41% of the outstanding shares of Verona Pharma have been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Verona Pharma has recently decreased by 5.29%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.61 News SentimentVerona Pharma has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Verona Pharma this week, compared to 3 articles on an average week.Search InterestOnly 13 people have searched for VRNA on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat Follows12 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Verona Pharma insiders have sold 2,549.13% more of their company's stock than they have bought. Specifically, they have bought $188,928.00 in company stock and sold $5,004,952.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Verona Pharma is held by insiders.Percentage Held by Institutions85.88% of the stock of Verona Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verona Pharma's insider trading history. Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VRNA Stock News HeadlinesVerona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 2,400 SharesNovember 14 at 9:14 AM | insidertrades.comDavid R. Ebsworth Acquires 39,360 Shares of Verona Pharma plc (NASDAQ:VRNA) StockNovember 8, 2024 | insidertrades.comTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.November 17, 2024 | Weiss Ratings (Ad)David Zaccardelli Sells 46,888 Shares of Verona Pharma plc (NASDAQ:VRNA) StockNovember 6, 2024 | insidertrades.comVerona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 4,800 SharesOctober 26, 2024 | insidertrades.comTruist Financial Issues a Buy Rating on Verona Pharma (VRNA)November 13, 2024 | markets.businessinsider.comCaligan picks up a stake in Verona Pharma, seeing an opportunity to generate more valueNovember 9, 2024 | cnbc.comVerona Pharma (NASDAQ:VRNA) Price Target Raised to $64.00November 8, 2024 | americanbankingnews.comSee More Headlines VRNA Stock Analysis - Frequently Asked Questions How have VRNA shares performed this year? Verona Pharma's stock was trading at $19.88 at the beginning of the year. Since then, VRNA stock has increased by 79.4% and is now trading at $35.66. View the best growth stocks for 2024 here. How were Verona Pharma's earnings last quarter? Verona Pharma plc (NASDAQ:VRNA) released its earnings results on Monday, November, 4th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.12. The company earned $5.62 million during the quarter, compared to analyst estimates of $2.31 million. When did Verona Pharma IPO? Verona Pharma (VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. Who are Verona Pharma's major shareholders? Verona Pharma's top institutional shareholders include RA Capital Management L.P. (6.27%), Maverick Capital Ltd. (5.24%), Frazier Life Sciences Management L.P. (4.23%) and Eventide Asset Management LLC (3.02%). Insiders that own company stock include David Zaccardelli, Mark W Hahn, Orbimed Advisors Llc, Kathleen A Rickard, Claire Poll, David R Ebsworth, Martin Edwards and Lisa Deschamps. View institutional ownership trends. How do I buy shares of Verona Pharma? Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Verona Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma investors own include Cisco Systems (CSCO), Philip Morris International (PM), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Home Depot (HD) and CrowdStrike (CRWD). Company Calendar Last Earnings11/04/2024Today11/16/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRNA CUSIPN/A CIK1657312 Webwww.veronapharma.com Phone011-44-0-2032834200FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$43.83 High Stock Price Target$64.00 Low Stock Price Target$33.00 Potential Upside/Downside+22.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,370,000.00 Net MarginsN/A Pretax Margin-2,698.40% Return on Equity-79.54% Return on Assets-43.49% Debt Debt-to-Equity Ratio0.93 Current Ratio13.03 Quick Ratio12.88 Sales & Book Value Annual Sales$460,000.00 Price / Sales6,197.09 Cash FlowN/A Price / Cash FlowN/A Book Value$1.63 per share Price / Book21.88Miscellaneous Outstanding Shares79,940,000Free Float76,103,000Market Cap$2.85 billion OptionableOptionable Beta0.42 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:VRNA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.